Mathematical modeling of the evolution of resistance and aggressiveness of high-grade serous ovarian cancer from patient CA-125 time series

K Jitmana; JI Griffiths; S Fereday; A DeFazio; D Bowtell; FR Adler

Journal article

Mathematical modeling of the evolution of resistance and aggressiveness of high-grade serous ovarian cancer from patient CA-125 time series

K Jitmana, JI Griffiths, S Fereday, A DeFazio, D Bowtell, FR Adler

Plos Computational Biology | PUBLIC LIBRARY SCIENCE | Published : 2024

DOI: 10.1371/journal.pcbi.1012073

Open access

Abstract

A time-series analysis of serum Cancer Antigen 125 (CA-125)levels was performed in 791 patients with high-grade serous ovarian cancer (HGSOC) from the Australian Ovarian Cancer Study to evaluate the development of chemoresistance and response to therapy. To investigate chemoresistance and better predict the treatment effectiveness, we examined two traits: resistance (defined as the rate of CA-125 change when patients were treated with therapy) and aggressiveness (defined as the rate of CA-125 change when patients were not treated). We found that as the number of treatment lines increases, the data-based resistance increases (a decreased rate of CA-125 decay). We use mathematical models of tw..

View full abstract

University of Melbourne Researchers

Julie Fereday Author

David Bowtell Author

Related Projects (3)

Molecular Epidemiology of Ovarian Research Institute

PUBLIC ABSTRACT A major obstacle to preventive strategies for ovarian cancer is the lack of recognized modifiable risk factors. Age, a pos..

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Grants

Awarded by City of Hope, NIH-CSBC

Awarded by U.S. Army Medical Research and Materiel Command

Awarded by NH\&MRC of Australia

Awarded by Cancer Foundation of Western Australia

Funding Acknowledgements

This research was supported in part by City of Hope, NIH-CSBC: U54 CA209978 to FRA. KJ received support from the Modeling the Dynamics of Life fund at the University of Utah. Australian Ovarian Cancer Study was supported by the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), NH\&MRC of Australia (199600, 400413, and 400281), Cancer Councils of NSW, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (191, 211 and 182). Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation. The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.